Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSánchez-Heras, A. Beatriz
dc.contributor.authorCastillejo, Adela
dc.contributor.authorGarcía-Díaz, Juan D.
dc.contributor.authorTeulé, Alexandre
dc.contributor.authorSánchez, Rosario
dc.contributor.authorLopez Fernandez, Adrià
dc.contributor.authorBalmaña Gelpí, Judith
dc.contributor.authorRobledo, Mercedes
dc.date.accessioned2021-08-27T08:50:12Z
dc.date.available2021-08-27T08:50:12Z
dc.date.issued2020-11-05
dc.identifier.citationSánchez-Heras AB, Castillejo A, García-Díaz JD, Robledo M, Teulé A, Sánchez R, et al. Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization. Cancers. 2020 Nov 5;12(11):3277.
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11351/6243
dc.descriptionHereditary leiomyomatosis; Renal cell cancer; FH gene
dc.description.abstractHereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancers (RCCs). We aimed to describe the genetics, clinical features and potential genotype-phenotype associations in the largest cohort of fumarate hydratase enzyme mutation carriers known from Spain using a multicentre, retrospective study of individuals with a genetic or clinical diagnosis of HLRCC. We collected clinical information from medical records, analysed genetic variants and looked for genotype-phenotype associations. Analyses were performed using R 3.6.0. software. We included 197 individuals: 74 index cases and 123 relatives. CLMs were diagnosed in 65% of patients, ULMs in 90% of women, RCys in 37% and RCC in 10.9%. Twenty-seven different pathogenic variants were detected, 12 (44%) of them not reported previously. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants (p = 0.0380, p = 0.0015 and p = 0.024, respectively). This is the first report of patients with HLRCC from Spain. The frequency of RCCs was lower than those reported in the previously published series. Individuals with missense pathogenic variants had higher frequencies of CLMs, ULMs and RCys.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;12(11)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCèl·lules canceroses
dc.subjectRonyons - Malalties - Espanya
dc.subject.meshLeiomyomatosis
dc.subject.mesh/genetics
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshSpain
dc.titleHereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers12113277
dc.subject.decsleiomiomatosis
dc.subject.decs/genética
dc.subject.decscarcinoma de células renales
dc.subject.decsEspaña
dc.relation.publishversionhttps://www.mdpi.com/2072-6694/12/11/3277
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sánchez-Heras AB] Cancer Genetic Counselling Unit, Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain. [Castillejo A] Molecular Genetics Unit, Hospital General Universitario de Elche, Elche, Spain. [García-Díaz JD] Clinical Genetics Unit, Department of Internal Medicine, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain. [Robledo M] Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Raras, CIBERER, Madrid, Spain. [Teulé A] Hereditary Cancer Program, Catalan Institute of Oncology, Instituto de Investigación Biomédica de Bellvitge, Hospitalet de Llobregat, Spain. [Sánchez R] Unidad Multidisciplinar de Enfermedades de Baja Prevalencia, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Alicante, Spain. [López-Fernández A, Balmaña J] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid33167498
dc.identifier.wos:000592895600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record